[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:pellucid-marginal-corneal-degeneration":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":34,"states":35},"Pellucid marginal corneal degeneration",4,[7,15,21,28],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07124910","Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases",[11],"Phase 3","RECRUITING","2026-08-26T02:15:00.557154Z","2026-05-05T02:43:29.681277Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT07135167","Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome",[11],"2026-08-26T02:17:41.695983Z","2026-05-05T02:43:28.709808Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT04094090","Safety and Effectiveness of the PXL-Platinum 330 System for Corneal Cross-Linking in Eyes With Corneal Ectasia",[25],"Phase 2","2026-08-26T02:17:21.315591Z","2026-05-05T02:43:27.604327Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT05516004","Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning",[25],"2026-08-26T02:17:27.435233Z","2026-05-05T02:35:31.723421Z",[],[]]